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Reply to the Editor:
We thank Drs Stamm and Steinhoff for
their comments. In the field of tissue-
engineered heart valves, the choice between
synthetic and biologic (either allogeneic or
xenogenic) scaffolds is a major concern. As
have many others, we hypothesized that the
best valve replacement remains a heart
valve. Porcine heart valves have been used
for decades in cardiac surgery with good
clinical results, especially in terms of du-
rability in elderly patients. In particular,
hemodynamic behavior of the latest gener-
ation of porcine bioprostheses, the stentless
porcine valves, was found to be similar to
that of native aortic valves.
These scaffolds, however, need preim-
plantation treatment to avoid acute xeno-
genic rejection. Decellularization seems a
promising choice, because it both induces a
decrease of cell-induced acute rejection
and may allow autologous cell recoloniza-
tion. Our study suggests that nonenzymatic
decellularization may be used without in-
ducing mechanical failure of the matrix in
vivo. Previous decellularization procedures,
such as deep osmotic shock (with distilled
water)1 or use of trypsin and ribonuclease,2
have resulted in graft failure.3 Adverse im-
mune reaction was advocated; however, we
observed that a less aggressive decellulariza-
tion procedure did not induce mechanical
failure after 4-month exposure in the sys-
temic arterial strain, suggesting that the de-
cellularization procedure was critical for the
in vivo outcome.
Stamm and coworkers4 used an enzy-
matic decellularization procedure, but they
reinforced the scaffold with a biodegrad-
able polymer coating. Short-terms results
were satisfactory, but little is known about
the long-term behavior of these polymers.
Previous long-term studies on biodegrad-
able scaffolds as heart valve substitutes
have reported fibrosis, retraction, and graft
dysfunction.5
As noted by Stamm and Steinhoff, co-
agulation and complement activation, with
the risk of collagen-induced platelet aggre-
gation early after implantation, are a major
concern with decellularized matrices. We
found no evidence of thrombus formation
on implanted decellularized scaffolds, and
thrombosis occurred only in a nondecellu-
larized xenograft. However, it should be
underlined that in our study all animals
received aspirin therapy (500 mg daily), as
in usual clinical practice with biologic
valves.
Finally, our study suggests that xenogenic
scaffolds decellularized through a nonenzy-
matic procedure do not induce matrix failure
in a sheep model, and interestingly allow
partial recellularization in vivo. Longer im-
plantation studies are mandatory to confirm
these mechanical results. Moreover, because
autologous cell recolonization of these decel-
lularized scaffolds remains only partial, other
strategies to induce complete recolonization
by proper autologous cells are needed.
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Lung transplantation in a patient
with Mounier-Kuhn syndrome
To the Editor:
We previously reported the first case of
successful lung transplantation in a patient
with Mounier-Kuhn syndrome.1 The pa-
tient was a 59-year-old woman with a his-
tory of bronchiectasis of unknown etiology
since childhood. The patient developed
very severe obstructive lung disease and
multiple episodes of pneumonia due to
Pseudomonas aeruginosa that necessitated
hospitalization. Computed chest tomogra-
phy and bronchoscopy were diagnostic of
Mounier-Kuhn syndrome. The patient un-
derwent bilateral lung transplantation, and
the degree of bronchomegaly was not as
pronounced as the tracheomegaly and posed
little difficulty during transplantation. The
patient had a difficult postoperative course,
with multiple failed extubations, P aerugi-
nosa pneumonia, and prolonged respiratory
failure necessitating tracheostomy. The pa-
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